S M Albert1, S Glied, H Andrews, Y Stern, R Mayeux. 1. Gertrude H. Sergievsky Center and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA. sma10@columbia.edu
Abstract
OBJECTIVE: To investigate primary care expenditures in the period before diagnosis of AD. METHODS: In a population-based sample of Medicare enrollees in New York City, person-level 1996 Medicare claims, summed over primary care encounters, were examined for people who developed AD in 1997 to 1998 and those who did not. RESULTS: People who developed AD were more likely to use Medicare outpatient and ambulatory care 1 to 2 years before diagnosis. Compared with respondents who did not develop AD, the excess cost for men was $1,167 (85% higher) and for women $239 (26% higher). Among elderly people > or = 75 years in the United States, the prodromal period of AD was associated with an excess Medicare-based primary care cost of $128.5 to $194.7 million. CONCLUSION: In addition to huge costs associated with AD after diagnosis, prediagnosis costs are an unrecognized source of expenditures related to the disease.
OBJECTIVE: To investigate primary care expenditures in the period before diagnosis of AD. METHODS: In a population-based sample of Medicare enrollees in New York City, person-level 1996 Medicare claims, summed over primary care encounters, were examined for people who developed AD in 1997 to 1998 and those who did not. RESULTS:People who developed AD were more likely to use Medicare outpatient and ambulatory care 1 to 2 years before diagnosis. Compared with respondents who did not develop AD, the excess cost for men was $1,167 (85% higher) and for women $239 (26% higher). Among elderly people > or = 75 years in the United States, the prodromal period of AD was associated with an excess Medicare-based primary care cost of $128.5 to $194.7 million. CONCLUSION: In addition to huge costs associated with AD after diagnosis, prediagnosis costs are an unrecognized source of expenditures related to the disease.
Authors: Cynthia L Leibson; Kirsten Hall Long; Jeanine E Ransom; Rosebud O Roberts; Steven L Hass; Amy M Duhig; Carin Y Smith; Jane A Emerson; V Shane Pankratz; Ronald C Petersen Journal: Alzheimers Dement Date: 2015-04-06 Impact factor: 21.566
Authors: Mary Sano; Carolyn W Zhu; Peter J Whitehouse; Steven Edland; Shelia Jin; Karin Ernstrom; Ronald G Thomas; Leon J Thal; Steven H Ferris Journal: Alzheimer Dis Assoc Disord Date: 2006 Oct-Dec Impact factor: 2.703
Authors: Brenda L Plassman; Kenneth M Langa; Gwenith G Fisher; Steven G Heeringa; David R Weir; Mary Beth Ofstedal; James R Burke; Michael D Hurd; Guy G Potter; Willard L Rodgers; David C Steffens; John J McArdle; Robert J Willis; Robert B Wallace Journal: Ann Intern Med Date: 2008-03-18 Impact factor: 25.391